If EGFR mutational testing has not been performed ahead of the first-line therapy—it is estimated that 15 to 35% of patients have insufficient tumor tissue for genotyping (56, 57), patients should be considered for repeated testing before starting second-line therapy. The gene discussed is EGFR; the disease is neoplasm.